Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients

被引:21
|
作者
Gerstenberg, G
Aoshima, T
Fukasawa, T
Yoshida, K
Takahashi, H
Higuchi, H
Murata, Y
Shimoyama, R
Ohkubo, T
Shimizu, T
Otani, K [1 ]
机构
[1] Yamagata Univ, Sch Med, Dept Neuropsychiat, Yamagata 9900585, Japan
[2] Akita Univ, Sch Med, Dept Psychiat, Akita 010, Japan
[3] Hirosaki Univ Hosp, Dept Pharm, Hirosaki, Aomori, Japan
关键词
fluvoxamine; fluvoxamino acid; steady-state plasma concentration; CYP2D6; cigarette smoking;
D O I
10.1097/00007691-200308000-00008
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The effects of the cytochrome P450 (CYP) 2D6 genotype and cigarette smoking on the steady-state plasma concentrations (C-SS) of fluvoxamine (FLV) and its demethylated metabolite fluvoxamino acid (FLA) were studied in 49 Japanese depressed patients receiving FLV 200 mg/d. The C-SS of FLV and FLA were measured by HPLC, and the wild-type allele (*1) and two mutated alleles causing absent (*5) or decreased (*10) CYP 2D6 activity were identified by PCR methods. The patients were divided into three genotype groups by the number of mutated alleles: 12 cases with no (*1/*1), 27 cases with one (*1/*5 and *1/*10), and 10 cases with two (*5/*10 and *10/*10) mutated alleles. The means +/- SD of the C-SS of FLV and FLA and the FLA/FLV ratio of all patients were 169.1 +/- 147.5 ng/mL, 83.9 +/- 52.7 ng/mL, and 0.71 +/- 0.50, respectively. The C-SS of FLV and FLA were not significantly different among the three genotype groups. However, the FLA/FLV ratio was significantly lower in the patients with one (P < 0.05) and two (P < 0.01) mutated alleles than in those with no mutated allele. There was no significant difference between nonsmokers (n = 34) and smokers (n = 15) in these values. In the stepwise multiple regression, the C-SS of FLA (P < 0.05) and FLA/FLV ratio (P < 0.001) showed significant negative correlations with the number of mutated alleles, and the FLA/FLV ratio was significantly (P < 0.05) lower in women than in men. The present study suggests that the CYP 2D6 genotype and cigarette smoking have no major impact on the C-SS of FLV and FLA, though CYP 2D6 is involved in the demethylation of FLV.
引用
收藏
页码:463 / 468
页数:6
相关论文
共 12 条
  • [1] Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients
    Gerstenberg, G
    Aoshima, T
    Fukasawa, T
    Yoshida, K
    Takahashi, H
    Higuchi, H
    Murata, Y
    Shimoyama, R
    Ohkubo, T
    Shimizu, T
    Otani, K
    PSYCHOPHARMACOLOGY, 2003, 167 (04) : 443 - 448
  • [2] Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients
    Gisa Gerstenberg
    Toshiaki Aoshima
    Takashi Fukasawa
    Keizo Yoshida
    Hitoshi Takahashi
    Hisashi Higuchi
    Yoshiko Murata
    Ritsuko Shimoyama
    Tadashi Ohkubo
    Tetsuo Shimizu
    Koichi Otani
    Psychopharmacology, 2003, 167 : 443 - 448
  • [3] Effects of Cigarette Smoking and Cytochrome P450 2D6 Genotype on Fluvoxamine Concentration in Plasma of Japanese Patients
    Katoh, Yasuhiro
    Uchida, Shinya
    Kawai, Masayoshi
    Takei, Noriyoshi
    Mori, Norio
    Kawakami, Junichi
    Kagawa, Yoshiyuki
    Yamada, Shizuo
    Namiki, Noriyuki
    Hashimoto, Hisakuni
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2010, 33 (02) : 285 - 288
  • [4] The Effects of Fluvoxamine on the Steady-State Plasma Concentrations of Escitalopram and Desmethylescitalopram in Depressed Japanese Patients
    Yasui-Furukori, Norio
    Tsuchimine, Shoko
    Kubo, Kazutoshi
    Ishioka, Masamichi
    Nakamura, Kazuhiko
    Inoue, Yoshimasa
    THERAPEUTIC DRUG MONITORING, 2016, 38 (04) : 483 - 486
  • [5] Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients
    Suzuki, A
    Otani, K
    Mihara, K
    Yasui, N
    Kaneko, S
    Inoue, Y
    Hayashi, K
    PHARMACOGENETICS, 1997, 7 (05): : 415 - 418
  • [6] Effects of the CYP2D6*10 Allele on the Steady-State Plasma Concentrations of Aripiprazole and Its Active Metabolite, Dehydroaripiprazole, in Japanese Patients With Schizophrenia
    Suzuki, Takeshi
    Mihara, Kazuo
    Nakamura, Akifumi
    Nagai, Goyo
    Kagawa, Shoko
    Nemoto, Kenji
    Ohta, Ikuya
    Arakaki, Hajime
    Uno, Tsukasa
    Kondo, Tsuyoshi
    THERAPEUTIC DRUG MONITORING, 2011, 33 (01) : 21 - 24
  • [7] Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia
    Mihara, K
    Kondo, T
    Yasui-Furukori, N
    Suzuki, A
    Ishida, M
    Ono, S
    Kubota, T
    Iga, T
    Takarada, Y
    de Vries, R
    Kaneko, S
    THERAPEUTIC DRUG MONITORING, 2003, 25 (03) : 287 - 293
  • [8] Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine
    Mihara, K
    Otani, K
    Suzuki, A
    Yasui, N
    Nakano, H
    Meng, XM
    Ohkubo, T
    Nagasaki, T
    Kaneko, S
    Tsuchida, S
    Sugawara, K
    Gonzalez, FJ
    PSYCHOPHARMACOLOGY, 1997, 133 (01) : 95 - 98
  • [9] Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine
    Kazuo Mihara
    K. Otani
    Akihito Suzuki
    Norio Yasui
    Hajime Nakano
    Xianmin Meng
    Tadashi Ohkubo
    Takako Nagasaki
    Sunao Kaneko
    Shigeki Tsuchida
    Kazunobu Sugawara
    Frank J. Gonzalez
    Psychopharmacology, 1997, 133 : 95 - 98
  • [10] Dose-Dependent Effect of the CYP2D6 Genotype on the Steady-state Fluvoxamine Concentration
    Watanabe, Junzo
    Suzuki, Yutaro
    Fukui, Naoki
    Sugai, Takuro
    Ono, Shin
    Inoue, Yoshimasa
    Someya, Toshiyuki
    THERAPEUTIC DRUG MONITORING, 2008, 30 (06) : 705 - 708